My Longevity Journey

  [mood, antibiotic] * Woman Successfully Treats Stage 4 Kidney Cancer And Celiac Disease With Cannabis Oil https://reset.me/story/woman-successfully-treats-stage-4-kidney-cancer-and-celiac-disease-with-cannabis-oil/ * [NEGATIVE] Cannabis May Impact Tumor Response to Immune Checkpoint Inhibitors ( link ) Patients who did not receive cannabis were 3.17 times more likely to respond to immunotherapy. Analyzed data from medical charts of 140 patients with advanced melanoma, non-small cell lung cancer (NSCLC), or renal cell carcinoma who were treated with nivolumab. While 89 patients received nivolumab alone, 51 patients also received medical cannabis. Patients who received both nivolumab and cannabis had lower response rates (RR) to nivolumab compared to patients who received nivolumab alone (15.9% vs 37.5%; odds ratio [OR] 3.13, P = .016). The biggest impact was seen in patients with RCC and melanoma, where 40.6% of patients who were not receiving cannabis responded to nivolumab, while on

  Antibiotics may indirectly improve progression-free survival (PFS) among patients with metastatic renal cell carcinoma (RCC) ( link ) Background: Diarrhea occurs in ~50% patients with mRCC receiving VEGFTKIs, and is a common cause of VEGFTKI Rx dose reductions/delays/interruptions. Stool bacteroides level directly correlates with diarrhea in these patients on Rx with VEGFTKI (Pal SK, Clinical Cancer Research 2015, PMID:26152743). Hypothesis was that mRCC patients on incidental antibiotics (ABX) which also target stool bacteroides will have less diarrhea, leading to improved Rx compliance, and improved outcomes on VEGFTKI. Results: Among patients prescribed antibiotics with bacteroides sensitivity, the median PFS was 18 months. Patients prescribed antibiotics without bacteroides sensitivity had a median PFS of 9 months, and patients not prescribed antibiotics had a median PFS of 8 months. The authors concluded that while validation is needed, in “these hypothesis generating data, inci

Clostridium butyricum CBM 588 probiotic strain ( link ) A probiotic containing a specific strain of the anaerobic, butyric acid-forming Gram-positive bacterium Clostridium butyricum (C. butyricum), with potential immunomodulatory, anti-inflammatory and antineoplastic activities. Clostridium butyricum MIYAIRI (CBM) 588 is the 588th MIYAIRI strain, isolated from a soil sample in Japan in 1963. Upon oral administration of C. butyricum CBM 588 probiotic strain, C. butyricum modulates the composition of the normal gastrointestinal (GI) microflora, by increasing the beneficial bacteria and decreasing the harmful bacteria, and helps maintain adequate colonization of the GI tract, thereby improving digestion and preventing GI disturbances. These bacteria and the butyric acid produced by them create an environment unfavorable to pathogens by adhering to human epithelial cells and forming a protective mucosal barrier. This prevents attachment of pathogens and reduces the risk of infection. By re